STUNNING development: More WOMEN than MEN at risk for COVID vaccine induced myocarditis (3rd dose)? Research suggests here females more at risk than males! Idiosyncratic? Christian Eugen Mueller,Basel
by Paul Alexander
Basel, Switzerland, cumulative distribution curve is alarming as fully shifted to the right beyond control & seems everyone regardless of gender has some elevated troponin (troponinemia, hs-cTnT)
‘Significant incidence of myocarditis after 3rd dose of anti-COVID 19 messenger RNA vaccine (author: Guillaume Le Pessec)’
This finding is opposite to what evidence had already accumulated with boys, males being usually at much more elevated risk, at a reported 9:1 ratio and this is very stunning. Is this idiosyncratic and thus a one-off? We need further data to unravel this gender differential to assess if it is stable or transitional.
Based on the presentation by Christian Eugen Mueller (Basel, Switzerland): “Myocardial Inflammation/Myocarditis After COVID-19 mRNA Booster Vaccination”
‘The aim of this study was to evaluate the real incidence of myocardial lesions during vaccinations with an mRNA vaccine in COVID 19 in a prospective manner and to evaluate possible preventive and protective measures to be applied in patients presenting with these lesions. asymptomatic myocardials.
This study was prospective single center with a control arm. The study population was composed of employees of the University Hospital of Basel in Switzerland, who had received a dose of the mRNA vaccine Pfizer-BioNTech or Moderna.
The primary endpoint was the occurrence of a myocardial lesion, defined by an increase in serum troponin above the norm, measured on D3 post-vaccination.
In case of elevation, a new assay was performed on D4 with the possibility of carrying out further cardiological explorations. In addition, patients with myocardial lesions were contraindicated to exercise until troponinemia decreased. In all cases, follow-up was continued until D30.'
The secondary endpoints were the comparison of the total population with patients who had been admitted for chest pain without any cardiac cause being found. Matching was performed on age, sex and history of coronary artery disease and peripheral atherosclerotic disease.
The second secondary endpoint was the occurrence of MACE at 30 days (death of cardiovascular origin, hospitalization for heart failure, ventricular arrhythmia and myocardial infarction).’
A main finding is the actual incidence of post-vaccination myocardial lesions is 2.8% or 28 per 1,000; 3.7% in women and 0.8% in men.
70% females comprised study population, mean age was 37 years and 92% had 3rd dose, under 2% had a cardiovascular history.
‘When comparing the population with myocardial lesions versus the population without myocardial lesions, the only risk factor found was female gender (p=0.03).’
835 patients were included; 777 (93%) received troponinemia assay on D3, 40 had increased troponinemia, in 18 causes other than the vaccine were identified that could explain the elevated troponinemia, in the other 22 (2.8%), the vaccine was defined as the cause.
Key consideration based on this study:
Prior to this study, there were no prospective data on post-vaccination myocardial lesions during vaccination with an mRNA vaccine. Only the most serious hospitalized myocarditis have been reported, mainly affecting men under 18 years of age.
The actual incidence of post-vaccination myocardial lesions is 2.8% vs 0.0035% of myocarditis in retrospective studies; this translates to 28 per 1,000 or 140 per 5,000
Myocardial lesions (injury) affect women more contrary to what is described in previous studies.
The possibility of repeated doses of vaccine in order to maintain effective vaccination coverage should lead to great caution regarding possible repeated myocardial lesions and their impact on possible cardiovascular complications.’